| Literature DB >> 16955246 |
Marco Jenzsch1, Stefan Gnoth, Martin Kleinschmidt, Rimvydas Simutis, Andreas Lübbert.
Abstract
In industry Escherichia coli is the preferred host system for the heterologous biosynthesis of therapeutic proteins that do not need posttranslational modifications. In this report, the development of a robust high-cell-density fed-batch procedure for the efficient production of a therapeutic hormone is described. The strategy is to guide the process along a predefined profile of the total biomass that was derived from a given specific growth rate profile. This profile might have been built upon experience or derived from numerical process optimization. A surprisingly simple adaptive procedure correcting for deviations from the desired path was developed. In this way the batch-to-batch reproducibility can be drastically improved as compared to the process control strategies typically applied in industry. This applies not only to the biomass but, as the results clearly show, to the product titer also.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16955246 PMCID: PMC1705514 DOI: 10.1007/s00449-006-0080-1
Source DB: PubMed Journal: Bioprocess Biosyst Eng ISSN: 1615-7591 Impact factor: 3.210